Jan 162023

7 Key Trends for the Global Life Sciences Industry in 2023

GLS Blog Contributor
, , , , , ,

Sidley’s 2023 Global Life Sciences Trendspotting Report maps out seven key trends in the life sciences industry globally, and identifies some regional trends in the U.S., China, and Europe which are likely to have global ramifications during the coming year.

The industry is experiencing increased regulatory and financial pressures in many areas. However, the current economic environment is also generating competitive advantages for the companies most adept at structuring their global product life cycles, supply chains, and business plans across the regions and countries which are still seeking to attract investment.

The key global life sciences trends to watch in 2023:

  1. With a Threatened Recession, Life Sciences Companies and Healthcare Providers Consider Alternative Liquidity Options
  2. Digital Health and Medical Artificial Intelligence Innovation Will Continue at a Breakneck Pace, Requiring a Robust Global Regulatory, Data, and Reimbursement Strategy
  3. Increasingly, Life Sciences and Healthcare Providers Proactively Consider Offensive Challenges to U.S. Government Agencies
  4. Life Sciences and Healthcare Enforcement and Litigation Activity is Increasing
  5. Shifting Regulatory Opportunities and Pitfalls Suggest Biotech Companies Should Pressure-Test Initial Development and Launch Destinations
  6. Environmental, Social, and Governance (ESG) Programs Will Be Subject to Increased Scrutiny
  7. New Privacy and Cyber Laws in U.S., Europe, and China Add Complexity While Enforcement Against Life Sciences Companies Is Rising

This post is as of the posting date stated above. Sidley Austin LLP assumes no duty to update this post or post about any subsequent developments having a bearing on this post.

GLS Blog Contributor

sidleyglsblog@sidley.com

You might also like
Forthcoming HHS Regulatory Actions and Opportunities Relevant for Pharmaceutical Manufacturers for the Rest of this Year and Next

Pharmaceutical manufacturers need to note some key forthcoming regulatory actions and opportunities which the Department of Health and Human Services (“HHS”) has recently published. Meena Datta and Catherine Starks give a bird’s eye view of the key points, the key dates and the stage which each new rule has reached.

China’s Generative AI Measures Could Affect Life Sciences Companies That Make Apps

Those medtech companies which embed AI into an app allowing healthcare professionals or patients to ask questions and to receive a response will probably need to comply with China’s new Interim Measures for the Management of Generative Artificial Intelligence Services (the “Measures”). Lianying Wang explains.

New EU Subsidies Rules Likely to Catch Global Life Sciences Companies

Given their extensive involvement in public procurement contracting, life sciences companies are likely to be heavily impacted by the EU’s Foreign Subsidies Regulation (the “FSR”), which has the potential to hold up tender awards over competition concerns. Michele Tagliaferri and Alessandra Moroni explain.